Alpha- versus beta-particle radiopeptide therapy in a human prostate cancer model (213Bi-DOTA-PESIN and 213Bi-AMBA versus 177Lu-DOTA-PESIN).
about
Long-Term Toxicity of 213Bi-Labelled BSA in MiceAn overview of targeted alpha therapy.Radioimmunotherapy with α-particle-emitting radionuclides.Inorganic chemistry in nuclear imaging and radiotherapy: current and future directions.Targeted alpha anticancer therapies: update and future prospectsHigh efficiency diffusion molecular retention tumor targeting.Comparison between internalizing anti-HER2 mAbs and non-internalizing anti-CEA mAbs in alpha-radioimmunotherapy of small volume peritoneal carcinomatosis using 212Pb.Challenges in nuclear medicine: innovative theranostic tools for personalized medicineThe effect of mini-PEG-based spacer length on binding and pharmacokinetic properties of a 68Ga-labeled NOTA-conjugated antagonistic analog of bombesin.Molecular targeted α-particle therapy for oncologic applications.²¹³Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experienceEvaluation of DOTA-chelated neurotensin analogs with spacer-enhanced biological performance for neurotensin-receptor-1-positive tumor targetingPEGylation, increasing specific activity and multiple dosing as strategies to improve the risk-benefit profile of targeted radionuclide therapy with 177Lu-DOTA-bombesin analogues.Influence of tumour size on the efficacy of targeted alpha therapy with (213)Bi-[DOTA(0),Tyr(3)]-octreotateImproved safety and efficacy of 213Bi-DOTATATE-targeted alpha therapy of somatostatin receptor-expressing neuroendocrine tumors in mice pre-treated with L-lysine.Radiopharmaceutical development of radiolabelled peptides.Bismuth compounds in medicinal chemistry.Targeting GRPR in urological cancers--from basic research to clinical application.Matching chelators to radiometals for radiopharmaceuticals.Next-generation therapy for residual prostate cancer.Current and potential applications of bismuth-based drugs.α- Versus β-Emitting Radionuclides for Pretargeted Radioimmunotherapy of Carcinoembryonic Antigen-Expressing Human Colon Cancer Xenografts.In Vivo Stabilization of a Gastrin-Releasing Peptide Receptor Antagonist Enhances PET Imaging and Radionuclide Therapy of Prostate Cancer in Preclinical Studies.Positron emission tomography (PET) imaging of prostate cancer with a gastrin releasing peptide receptor antagonist--from mice to men.Orthotopic administration of (213)Bi-bevacizumab inhibits progression of PC3 xenografts in the prostate.Therapeutic efficacy and toxicity of 225Ac-labelled vs. 213Bi-labelled tumour-homing peptides in a preclinical mouse model of peritoneal carcinomatosis.Atomic mass tag of bismuth-209 for increasing the immunoassay multiplexing capacity of mass cytometry.Profiling gastrin-releasing peptide receptor in prostate tissues: clinical implications and molecular correlates.Curative Multicycle Radioimmunotherapy Monitored by Quantitative SPECT/CT-Based Theranostics, Using Bispecific Antibody Pretargeting Strategy in Colorectal Cancer.DNA damage in leukocytes after internal ex-vivo irradiation of blood with the α-emitter Ra-223.Prostate Cancer Theranostics Targeting Gastrin-Releasing Peptide Receptors.In Vivo Evaluation of a Bombesin Analogue Labeled with Ga-68 and Co-55/57.
P2860
Q27317386-FB736DBC-BE20-4239-9772-71B2C3D10F24Q34238513-C431FEE4-9244-46B8-B8A6-E08D96989C23Q34419562-1E6C67D5-09D6-4F9A-BC6E-ABBDD87E28D1Q34460892-4C6CE1DB-114E-49DA-93EC-C2BA0082CFA9Q34511439-C8AEB788-FF1C-429B-85C5-AF87466A21C6Q34625694-CB3AF40F-44D4-45A1-9F36-3C69C6122875Q34903258-5784174D-64A1-46E6-95C3-E8639E94D635Q35104505-57A86BDC-5632-4531-95AF-6CA25C5FC482Q35208747-F87C2093-5E91-4BD3-B494-001A45F46785Q35814989-2FD27FD7-6B4F-467D-B21D-B7B178EB69D3Q35917106-213A1002-EE3F-407A-B904-CEC3AB51395CQ36122563-AA95FE67-7ECB-491F-B7D9-3F20795E6330Q36338484-870C4C3D-A237-4C40-93B6-A17693C3DA11Q36484229-82F44485-4B21-4150-9A8A-F2D0A223A1ADQ37427273-89084907-7D2A-4ED6-9299-612E1CF11028Q37990399-0EFD337E-00D9-488B-86B3-7A3385A767B3Q38031636-C8F9B637-0CF2-4BCF-A9E5-669AEC51A914Q38090926-52C69FB1-5D6A-4E35-A415-448E424000F8Q38156660-2F1ECA15-1B75-4A39-A5A7-AFCB724F6C6EQ38159804-EF4B0377-A4B2-46D4-9098-5AEFA81FF04FQ38253836-973A2B6D-4117-4825-8291-190D73E756F0Q38715106-D2B9775E-B4F3-4B2C-9740-9B0AD94DD63AQ38925590-0B19620F-D5E4-4BD8-8240-623935A94128Q39242936-3D835A26-79A6-4497-BEBB-B927F7558320Q39340788-02FDD9C8-1A61-4F19-85F4-A8445C4D445EQ39413582-62972B49-AEEE-4143-8DAA-070C89E84EDAQ45074785-608AE860-E2A6-45B3-AFB8-241C359E870EQ45354634-62FC2FE9-8439-4919-BCBF-4590EF2A1926Q47926790-23EB5CCE-8D2D-4D8D-95D4-40EAA778DC04Q48042018-357D51E5-CACE-420B-80AA-B82E94814309Q48096316-AB08924F-302C-4869-AEE1-B8D4C8D30C12Q48105870-2E5A78BE-2550-4787-B4B7-9D17A93F3A5E
P2860
Alpha- versus beta-particle radiopeptide therapy in a human prostate cancer model (213Bi-DOTA-PESIN and 213Bi-AMBA versus 177Lu-DOTA-PESIN).
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Alpha- versus beta-particle ra ...... AMBA versus 177Lu-DOTA-PESIN).
@en
Alpha- versus beta-particle radiopeptide therapy in a human prostate cancer model
@nl
type
label
Alpha- versus beta-particle ra ...... AMBA versus 177Lu-DOTA-PESIN).
@en
Alpha- versus beta-particle radiopeptide therapy in a human prostate cancer model
@nl
prefLabel
Alpha- versus beta-particle ra ...... AMBA versus 177Lu-DOTA-PESIN).
@en
Alpha- versus beta-particle radiopeptide therapy in a human prostate cancer model
@nl
P2093
P1433
P1476
Alpha- versus beta-particle ra ...... AMBA versus 177Lu-DOTA-PESIN).
@en
P2093
Alfred Morgenstern
Anne Provencher-Bolliger
Damian Wild
Frank Bruchertseifer
Hanwen Zhang
Helmut R Maecke
Jean-Claude Reubi
Julie Boisclair
Michael Frischknecht
P304
P356
10.1158/0008-5472.CAN-10-1186
P407
P577
2011-01-18T00:00:00Z